MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer

Quan Huang, Lei Li, Lin Li, Hui Chen, Yongyan Dang, Jishen Zhang, Naimin Shao, Hong Chang, Zhengjie Zhou, Chongyi Liu,

Oncotarget · 2016 · 18 citations · 30 references

DOIFull text

Open access

Concepts

Abstract

// Quan Huang 1, 2, * , Lei Li 1, 2, * , Lin Li 1, * , Hui Chen 2 , Yongyan Dang 2 , Jishen Zhang 1 , Naimin Shao 2 , Hong Chang 2 , Zhengjie Zhou 2 , Chongyi Liu 2 , Bingwei He 2 , Haifeng Wei 1 , Jianru Xiao 1 1 Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR China 2 Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, PR China * These authors have contributed equally to this work Correspondence to: Jianru Xiao, email: jianru_xiao12345@163.com Haifeng Wei, email: haifeng_wei123@163.com Keywords: dendrimer, MDM2, gene delivery, siRNA, non-small cell lung cancer Received: March 22, 2016      Accepted: May 13, 2016      Published: June 01, 2016 ABSTRACT Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the five-year survival rate is lower in advanced NSCLC patients. Chemotherapy is a widely used strategy in NSCLC treatment, but is usually limited by poor therapeutic efficacy and adverse effects. Therefore, a new therapeutic regimen is needed for NSCLC treatment. Gene therapy is a new strategy in the treatment of NSCLC. However, the lack of efficient and low toxic vectors remains the major obstacle. Here, we developed a biocompatible dendrimer as a non-viral vector for the delivery of mouse double minute2 (MDM2) siRNA in vitro and in vivo to treat NSCLC. The triazine-modified dendrimer efficiently stimulates the down-regulation of MDM2 gene in NSCLC PC9 cells, which induces significant cell apoptosis through the activation of apoptosis markers such as caspase-8 and poly(ADP-ribose) polymerase (PARP) cleavage. Furthermore, the dendrimer/MDM2 siRNA polyplexes showed excellent activity in the inhibition of tumor growth in a PC9 xenograft tumor model. These results suggested that inhibition the expression of MDM2 might be a potential target in NSCLC treatment.

References

30